DERACOXIB

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H14F3N3O3S
Molecular Weight	397.372
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1F)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)F

InChI

InChIKey=WAZQAZKAZLXFMK-UHFFFAOYSA-N

InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

HIDE SMILES / InChI

Molecular Formula	C17H14F3N3O3S
Molecular Weight	397.372
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdf
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/21985349

Deracoxib (trade name Deramaxx, Novartis) is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine for the control of postoperative pain and inflammation associated with orthopedic and dental surgery and for the control of pain and inflammation associated with osteoarthritis in dogs. Data indicate that deracoxib inhibits the production of PGE1 and 6-keto PGF1 by its inhibitory effects on prostaglandin biosynthesis. Deracoxib was shown to have antitumor effect against transitional cell carcinoma of the urinary bladder.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Osteosarcoma cell growth 1 Target ID: Osteosarcoma cell growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/16334957	Inhibitor 8504		150.0 µM [IC50]
Prostaglandin G/H synthase 2 51 Target ID: O19183 Gene ID: 791253.0 Gene Symbol: PTGS2 Target Organism: Equus caballus (Horse) Sources: http://www.ncbi.nlm.nih.gov/pubmed/21219338	Inhibitor 8504		0.39 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Osteosarcoma 22 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16334957	Primary	Basic research	Unknown Approved Use Unknown
Osteoarthritis pain and inflammation 1 Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdf	Palliative	Approved 8583	DERAMAXX (deracoxib) Approved Use Osteoarthritis pain and inflammation Launch Date 2002
Postoperative orthopedic pain and inflammation 1 Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdf	Palliative	Approved 8583	DERAMAXX (deracoxib) Approved Use For postoperative orthopedic pain and inflammation Launch Date 2002
Postoperative dental pain and inflammation 1 Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdf	Palliative	Approved 8583	DERAMAXX (deracoxib) Approved Use For postoperative dental pain and inflammation Launch Date 2002

PubMed

Title	Date	PubMed
Spontaneous pneumothorax in a dog secondary to Dirofilaria immitis infection.	2010-11	21088191
Proximal duodenal perforation in three dogs following deracoxib administration.	2010-07-09	20610698
In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.	2010-06	20004922
Characterization and modulation of canine mast cell derived eicosanoids.	2010-05-15	20036014
Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs.	2010-03	20187838
Use of deracoxib during intense rehabilitation exercises.	2010	21155163
Randomised controlled clinical trial for the use of deracoxib during intense rehabilitation exercises after tibial plateau levelling osteotomy.	2010	20740263
Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs.	2009-10	19795939
Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs.	2009-08	19614837
Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).	2008-07-01	18593321
Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs.	2008-04	18380576
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.	2007-07	17492455
Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs.	2007-03	17331013
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs.	2007	17447224
Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs.	2006-12-26	17186840
Effect of short-term sequential administration of nonsteroidal anti-inflammatory drugs on the stomach and proximal portion of the duodenum in healthy dogs.	2006-10	17014336
Disposition of deracoxib in cats after oral administration.	2006-04-14	16611933
Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs.	2006-04	16579752
Extraskeletal osteosarcoma associated with retained surgical sponge in a dog.	2006-03	16617710
The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model.	2006-01	16409407
Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.	2005-11	16334957
Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003).	2005-10-01	16220672
Nonsteroidal antiinflammatory drugs: a review.	2005-09-06	16141181
Determination of deracoxib in feline plasma samples using high performance liquid chromatography.	2005-05-05	15797537
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis.	2005-05	15934608
Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum.	2005-01	15651739
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.	2004-04	15077695
Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.	2002	12584683

Patents

Sample Use Guides

In Vivo Use Guide

Osteoarthritis Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed. Postoperative Orthopedic Pain and inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.

Route of Administration: Oral

In Vitro Use Guide

Deracoxib was used for the treatment of Canine bone marrow derived cultured mast cells (cBMCMCs) at the concentration 1uM and incubated for 24 h to strongly inhibit PGD2 and PGE2 production.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:21 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:21 GMT 2025`
Record UNII	VX29JB5XWV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DERACOXIB [MI]

Preferred Name

English

DERACOXIB

Official Name

English

4-(3-(DIFLUOROMETHYL)-5-(3-FLUORO-4-METHOXYPHENYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE

Systematic Name

English

NSC-758935

Code

English

deracoxib [INN]

Common Name

English

Deracoxib [WHO-DD]

Common Name

English

DERACOXIB [GREEN BOOK]

Common Name

English

SC-59046

Code

English

DERACOXIB [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1323